-
1
-
-
0022621521
-
Risk factors for cytomegalovirus infection after human marrow transplantation
-
Myers JD. Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478-488.
-
(1986)
J Infect Dis
, vol.153
, pp. 478-488
-
-
Myers, J.D.1
Flournoy, N.2
Thomas, E.D.3
-
2
-
-
0025121087
-
Cytomegalovirus infections after allogeneic bone marrow transplantation
-
Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis. 1999;12(suppl 7):S776-S792.
-
(1999)
Rev Infect Dis
, vol.12
, Issue.SUPPL. 7
-
-
Winston, D.J.1
Ho, W.G.2
Champlin, R.E.3
-
3
-
-
2942733177
-
Management of CMV infections: Recommendations from the infectious diseases working party of the EBMT
-
Ljungman P, Reusser P, de la Camara R, et al, for the Infectious Disease Working Party of the European Group for Blood and Marrow Transplantation. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004;33:1075-1081.
-
(2004)
Bone Marrow Transplant
, vol.33
, pp. 1075-1081
-
-
Ljungman, P.1
Reusser, P.2
De La Camara, R.3
-
4
-
-
2942733565
-
Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation
-
Boeckh M, Fries B, Garrett NW. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant. 2004;8(suppl 5):19-27.
-
(2004)
Pediatr Transplant
, vol.8
, Issue.SUPPL. 5
, pp. 19-27
-
-
Boeckh, M.1
Fries, B.2
Garrett, N.W.3
-
5
-
-
0027455417
-
Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
-
Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173-178.
-
(1993)
Ann Intern Med
, vol.118
, pp. 173-178
-
-
Goodrich, J.M.1
Bowden, R.A.2
Fisher, L.3
Keller, C.4
Schoch, G.5
Meyers, J.D.6
-
6
-
-
0027531101
-
Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial
-
Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179-184.
-
(1993)
Ann Intern Med
, vol.118
, pp. 179-184
-
-
Winston, D.J.1
Ho, W.G.2
Bartoni, K.3
-
7
-
-
0029800728
-
Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
-
Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-4071.
-
(1996)
Blood
, vol.88
, pp. 4063-4071
-
-
Boeckh, M.1
Gooley, T.A.2
Myerson, D.3
Cunningham, T.4
Schoch, G.5
Bowden, R.A.6
-
8
-
-
0025758922
-
A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV Study Group
-
Schmidt GM, Horak D, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: the City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005-1011.
-
(1991)
N Engl J Med
, vol.324
, pp. 1005-1011
-
-
Schmidt, G.M.1
Horak, D.2
Niland, J.C.3
Duncan, S.R.4
Forman, S.J.5
Zaia, J.A.6
-
9
-
-
0034070233
-
Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation
-
Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:765-769.
-
(2000)
Bone Marrow Transplant
, vol.25
, pp. 765-769
-
-
Mori, T.1
Okamoto, S.2
Matsuoka, S.3
-
10
-
-
0036272556
-
Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation
-
Mori T, Okamoto S, Watanabe R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:777-782.
-
(2002)
Bone Marrow Transplant
, vol.29
, pp. 777-782
-
-
Mori, T.1
Okamoto, S.2
Watanabe, R.3
-
11
-
-
19944434167
-
Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic bone marrow transplantation: A single-center experience in Korea
-
Choi S-M, Lee D-G, Choi J-H, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic bone marrow transplantation: a single-center experience in Korea. Int J Hematol. 2005;81:69-74.
-
(2005)
Int J Hematol
, vol.81
, pp. 69-74
-
-
Choi, S.-M.1
Lee, D.-G.2
Choi, J.-H.3
-
12
-
-
21444434397
-
Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation
-
Mori T, Aisa Y, Nakazato T, Okamoto S. Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2005;81:439-440.
-
(2005)
Int J Hematol
, vol.81
, pp. 439-440
-
-
Mori, T.1
Aisa, Y.2
Nakazato, T.3
Okamoto, S.4
-
13
-
-
12144288318
-
Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation
-
Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:431-434.
-
(2004)
Bone Marrow Transplant
, vol.33
, pp. 431-434
-
-
Mori, T.1
Mori, S.2
Kanda, Y.3
-
15
-
-
0029842170
-
Valaciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections
-
Perry CM, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 1996;52:754-772.
-
(1996)
Drugs
, vol.52
, pp. 754-772
-
-
Perry, C.M.1
Faulds, D.2
-
16
-
-
0019720660
-
The in vitro activity of acyclovir and related compounds against cytomegalovirus infections
-
Tyms AS, Scamans EM, Naim HM. The in vitro activity of acyclovir and related compounds against cytomegalovirus infections. J Antimicrob Chemother. 1981;8:65-72.
-
(1981)
J Antimicrob Chemother
, vol.8
, pp. 65-72
-
-
Tyms, A.S.1
Scamans, E.M.2
Naim, H.M.3
-
17
-
-
0023281112
-
In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir
-
Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis. 1987;6:255-261.
-
(1987)
Diagn Microbiol Infect Dis
, vol.6
, pp. 255-261
-
-
Cole, N.L.1
Balfour Jr., H.H.2
-
18
-
-
0023873331
-
Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation
-
Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318:70-75.
-
(1988)
N Engl J Med
, vol.318
, pp. 70-75
-
-
Meyers, J.D.1
Reed, E.C.2
Shepp, D.H.3
-
19
-
-
0028274678
-
Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
-
European Acyclovir for CMV Prophylaxis Study Group
-
Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343:749-753.
-
(1994)
Lancet
, vol.343
, pp. 749-753
-
-
Prentice, H.G.1
Gluckman, E.2
Powles, R.L.3
-
20
-
-
0037089419
-
Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants
-
Ljungman P, de la Camara R. Milpied N. et al, and the Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99:3050-3056.
-
(2002)
Blood
, vol.99
, pp. 3050-3056
-
-
Ljungman, P.1
De La Camara, R.2
Milpied, N.3
-
21
-
-
0037444029
-
Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation
-
Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC, and the Valacyclovir Cytomegalovirus Study Group. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36:749-758.
-
(2003)
Clin Infect Dis
, vol.36
, pp. 749-758
-
-
Winston, D.J.1
Yeager, A.M.2
Chandrasekar, P.H.3
Snydman, D.R.4
Petersen, F.B.5
Territo, M.C.6
-
23
-
-
0029075453
-
HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method
-
Kurihara T, Hayashi J, Matusoka T, et al. HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method. Biomed Res. 1995;16:125-129.
-
(1995)
Biomed Res
, vol.16
, pp. 125-129
-
-
Kurihara, T.1
Hayashi, J.2
Matusoka, T.3
-
24
-
-
0027768955
-
Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers
-
Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595-605.
-
(1993)
Clin Pharmacol Ther
, vol.54
, pp. 595-605
-
-
Weller, S.1
Blum, M.R.2
Doucette, M.3
-
25
-
-
0028883462
-
Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans
-
Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39:2759-2764.
-
(1995)
Antimicrob Agents Chemother
, vol.39
, pp. 2759-2764
-
-
Soul-Lawton, J.1
Seaber, E.2
On, N.3
Wootton, R.4
Rolan, P.5
Posner, J.6
-
26
-
-
0034882831
-
Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: A single institution retrospective cohort analysis
-
Vusirikala M, Wolff SN. Stein RS, et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant. 2001;28:265-270.
-
(2001)
Bone Marrow Transplant
, vol.28
, pp. 265-270
-
-
Vusirikala, M.1
Wolff, S.N.2
Stein, R.S.3
-
27
-
-
6844258215
-
A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection: AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group
-
Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection: AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis. 1998;177:48-56.
-
(1998)
J Infect Dis
, vol.177
, pp. 48-56
-
-
Feinberg, J.E.1
Hurwitz, S.2
Cooper, D.3
-
28
-
-
0033551348
-
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
-
Lowance D, Neumayer H-H, Legendre CM, et al, for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999;340:1462-1470.
-
(1999)
N Engl J Med
, vol.340
, pp. 1462-1470
-
-
Lowance, D.1
Neumayer, H.-H.2
Legendre, C.M.3
-
29
-
-
22344434696
-
Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: Thromobotic microangiopathy after hematopoietic stem cell transplantation
-
Ho VT, Cutler C, Carter S, et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thromobotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571-575.
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 571-575
-
-
Ho, V.T.1
Cutler, C.2
Carter, S.3
|